Stephen Tilles
Overview
Explore the profile of Stephen Tilles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou X, Dunham D, Sindher S, Long A, Fernandes A, Chang I, et al.
Allergy
. 2024 Sep;
80(3):762-774.
PMID: 39291303
Background: Omalizumab (XOLAIR®)-assisted multi-food oral immunotherapy (mOIT) has been shown to safely, effectively, and rapidly desensitize patients with multiple food allergies. In our clinical trial (NCT02626611) on omalizumab-assisted mOIT, different...
2.
Mack D, Dribin T, Turner P, Wasserman R, Hanna M, Shaker M, et al.
J Allergy Clin Immunol
. 2024 Apr;
153(6):1621-1633.
PMID: 38597862
Background: Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included...
3.
Jara M, Walker E, Tilles S, Anagnostou A
Ann Allergy Asthma Immunol
. 2024 Mar;
132(6):778-780.
PMID: 38479712
No abstract available.
4.
Du Toit G, Brown K, Vereda A, Irani A, Tilles S, Ratnayake A, et al.
NEJM Evid
. 2024 Feb;
2(11):EVIDoa2300145.
PMID: 38320526
BACKGROUND: Peanut allergy is a common childhood allergy, and the only approved treatment for children 4 to 17 years of age is peanut allergen powder-dnfp (PTAH) oral immunotherapy. METHODS: For...
5.
Bird J, Nilsson C, Brown K, Pham T, Tilles S, Du Toit G, et al.
J Allergy Clin Immunol Glob
. 2023 Oct;
2(3):100120.
PMID: 37779517
Background: Oral immunotherapy containing peanut () allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals...
6.
Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson S, Latremouille-Viau D, et al.
Ann Allergy Asthma Immunol
. 2023 Feb;
130(5):649-656.e4.
PMID: 36738781
Background: Peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) is the first oral immunotherapy indicated for children aged 4 to 17 years with peanut allergy. There are limited real-world data on patients...
7.
Corren J, Larson D, Altman M, Segnitz R, Avila P, Greenberger P, et al.
J Allergy Clin Immunol
. 2022 Oct;
151(1):192-201.
PMID: 36223848
Background: Thymic stromal lymphopoietin (TSLP) has been shown to play a central role in the initiation and persistence of allergic responses. Objective: We evaluated whether tezepelumab, a human monoclonal anti-TSLP...
8.
Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, et al.
Adv Ther
. 2021 Jul;
38(8):4321-4332.
PMID: 34236672
Introduction: The phase 3 trial PALISADE, comparing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) oral immunotherapy versus placebo in peanut-allergic children, reported that a significantly higher percentage of PTAH-treated participants tolerated...
9.
Sindher S, Long A, Purington N, Chollet M, Slatkin S, Andorf S, et al.
Front Immunol
. 2020 Dec;
11:625796.
PMID: 33329616
[This corrects the article DOI: 10.3389/fimmu.2018.02689.].
10.
Sharma V, Jobrack J, Cerenzia W, Tilles S, Ryan R, Sih-Meynier R, et al.
PLoS One
. 2020 Dec;
15(12):e0241648.
PMID: 33270629
Rationale: Food allergy is documented to result in considerable morbidity, negative impact on quality of life, and substantial medical care costs. Although anecdotal data suggest widely varying practices in the...